HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma
Crossref DOI link: https://doi.org/10.1007/s10549-017-4453-8
Published Online: 2017-08-10
Published Print: 2017-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hou, Yanjun
Nitta, Hiroaki
Wei, Lai
Banks, Peter M.
Portier, Bryce
Parwani, Anil V.
Li, Zaibo http://orcid.org/0000-0003-1325-1696
License valid from 2017-08-10